Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

11.47 +0.53 (+4.84%)
Streaming Delayed Price Updated: 2:56 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,153
Open 10.73
Bid (Size) 11.48 (2)
Ask (Size) 11.60 (1)
Prev. Close 10.94
Today's Range 10.67 - 11.66
52wk Range 5.830 - 26.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Avis Budget, Civitas, Open Lending, and Zenas BioPharma and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+27.3%
+27.3%
1 Month
+17.6%
+17.6%
3 Month
+78.4%
+78.4%
6 Month
-7.9%
-7.9%
1 Year
-36.8%
-36.8%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadline - ZBIO
From Pomerantz LLP
Via GlobeNewswire
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Avis Budget, NET Power, Open Lending, and Zenas BioPharma and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ZBIO Stock Notice: Zenas BioPharma, Inc. Stockholders are Encouraged to Contact Shareholder Rights Law Firm Robbins LLP for Information About the ZBIO Class Action
From Robbins LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contact the Law Firm for Information on Leading the Zenas BioPharma, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
ZBIO Investors Have the Opportunity to Lead the Zenas BioPharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, and Zenas BioPharma and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ZBIO
From Pomerantz LLP
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
From The Rosen Law Firm PA
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
ZBIO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
ZENAS BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
Zenas BioPharma, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against ZBIO
From Robbins LLP
Via GlobeNewswire

Frequently Asked Questions

Is Zenas BioPharma, Inc. - Common Stock publicly traded?
Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.
What exchange does Zenas BioPharma, Inc. - Common Stock trade on?
Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?
The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market
What is the current price of Zenas BioPharma, Inc. - Common Stock?
The current price of Zenas BioPharma, Inc. - Common Stock is 11.47
When was Zenas BioPharma, Inc. - Common Stock last traded?
The last trade of Zenas BioPharma, Inc. - Common Stock was at 05/22/25 02:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.